Proxy Votes Now

Home › Funds › ALPS ETF Trust › ALPS Medical Breakthroughs ETF

ALPS Medical Breakthroughs ETF (SBIO) proxy voting record 2025-2026

Fund family: ALPS ETF Trust · Filed by ALPS ETF Trust (CIK 1414040) · SEC series S000047823

Ticker: SBIO (C000150206)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 582 with, 0 against, 0 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 0 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with ALPS ETF Trust as a whole

The same two figures as ALPS ETF Trust’s manager page (16,050 ballot items across 21 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsALPS ETF TrustItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)76.1%55392.2%13,954
Backed environmental and social shareholder proposals at US companiesn/a09.2%369

No item-level comparison with other ALPS ETF Trust funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 83.7% of this fund’s 582 such votes could be given a sector; the other 95 (16.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care48700.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections3210
Audit-related910
Say-on-Pay800
Compensation500
Corporate Governance310
Capital Structure180
Extraordinary Transactions50
Other Social Issues10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Edgewise Therapeutics, Inc.June 4, 2026$4M50
Oruka Therapeutics, Inc.June 2, 2026$3M40
Dianthus Therapeutics, Inc.May 21, 2026$3M50
Tarsus Pharmaceuticals, Inc.June 25, 2026$3M60
Travere Therapeutics, Inc.May 19, 2026$3M140
Viking Therapeutics, Inc.May 19, 2026$3M40
Acadia Pharmaceuticals Inc.May 29, 2026$3M60
Vericel CorporationApril 29, 2026$3M90

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

597 ballot items at 88 meetings in 2025-2026. Download all votes (CSV)

About this fund’s record

In the 2025-2026 proxy season, ALPS Medical Breakthroughs ETF (SBIO) voted at 88 shareholder meetings of 88 companies, on 597 ballot items in all. Where management made a recommendation, the fund followed it on 100.0% of the items and voted against it 0 times. It voted FOR the board's own proposals less often than ALPS ETF Trust's funds as a whole (76.1% against 92.2%). 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of ALPS ETF Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.